(Press-News.org) Researchers from Mount Sinai School of Medicine have for the first time used several imaging techniques to prove the efficacy of a promising new treatment for atherosclerosis—the build-up of plaque in artery walls that can lead to a heart attack. Using positron-emission tomography (PET)/computed tomography (CT) and magnetic resonance imaging (MRI), the research team showed that dalcetrapib, a novel treatment for atherosclerosis, prevented the progression of disease and reduced vascular inflammation over 24 months. The data are published in the September 12 issue of The Lancet.
The dal-PLAQUE study is the longest placebo-controlled, active-drug MRI study to date, and the first to use a variety of noninvasive imaging techniques to visualize arterial plaque. In this Phase IIB, double-blind, multicenter trial, Mount Sinai researchers evaluated 130 study participants with atherosclerosis who were randomized to receive dalcetrapib or placebo for 24 months. To determine the efficacy of dalcetrapib, the team used MRI to analyze plaque progression in the arterial wall and PET/CT to assess arterial inflammation. The images showed that dalcetrapib significantly reduced atherosclerotic disease progression and inflammation.
"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said Zahi A. Fayad, PhD, Professor of Radiology and Medicine in the Division of Cardiology, and the Director of the Translational and Molecular Imaging Institute at Mount Sinai School of Medicine, and lead author on the study. "We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease."
Lowering of the so-called bad cholesterol (low-density lipoprotein) through statin use, is a highly effective method of improving cardiovascular outcome in a broad range of patients. However, despite optimal use, significant risk remains. Dalcetrapib is part of a class of drugs called cholesteryl ester transfer protein inhibitors that raise high-density lipoprotein (HDL) commonly known as "good" cholesterol. Research has shown that raising HDL cholesterol may reduce coronary artery disease risk. In the dal-PLAQUE study, patients who received dalcetrapib saw a 31 percent increase in HDL cholesterol levels, as examined through MRI. The PET/CT scans showed that inflammation levels in the carotid artery of patients taking dalcetrapib were significantly reduced, yet stayed the same in the placebo group.
"Considering the concerns surrounding this class of drugs, MRI and PET/CT imaging are valuable biomarkers for assessing safety and efficacy," said Dr. Fayad. "The first drug in this class, torcetrapib, effectively increased HDL cholesterol but caused a significant increase in mortality due to vascular inflammation. Through noninvasive imaging, we were able to determine that the inflammation associated with torcetrapib was not found in dalcetrapib. The success of this trial indicates that noninvasive imaging may be a critical tool for evaluating other investigational treatments for heart disease as well."
As a leader in cardiovascular medicine and imaging, Mount Sinai is establishing a center that will use state of the art imaging technology to help treat and prevent atherosclerosis, heart attack, and heart failure. In collaboration with the Mount Sinai Cardiovascular Institute and Mount Sinai Heart, the new Translational and Molecular Imaging Institute will continue to innovate, validate and translate new tools for the improvements of patients care.
"Cardiovascular disease impacts millions of people, and costs billions of dollars each year in the United States alone," said Valentin Fuster, MD, PhD, Director of Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at The Mount Sinai Medical Center. "As demonstrated in the dal-PLAQUE study, Dr. Fayad has brought Mount Sinai to the forefront of using noninvasive imaging to help study, prevent, and treat heart disease. We look forward to using MRI and PET/CT in future clinical trials."
INFORMATION:
The centers that participated in the dal-PLAQUE trial include: Baylor College of Medicine, Houston; Cardiovascular Imaging Technologies, Kansas; University of Minnesota; The Mount Sinai Medical Center, New York; University of Washington School of Medicine, Seattle; Jacksonville Center for Clinical Research; Iredell Internal Medicine; Sterling Research Group; Metabolic and Atherosclerosis Research Center, Cincinnati; William Beaumont Hospital Health Center; Montreal Heart Institute.
Dr. Fayad receives financial compensation as a scientific advisory board member for F. Hoffman-La Roche Ltd, the sponsor of this study.
END
EVANSTON, Ill. --- A new Northwestern University study provides compelling evidence that human males are biologically wired to care for their offspring, conclusively showing for the first time that fatherhood lowers a man's testosterone levels.
The effect is consistent with what is observed in many other species in which males help take care of dependent offspring. Testosterone boosts behaviors and other traits that help a male compete for a mate. After they succeed and become fathers, "mating-related" activities may conflict with the responsibilities of fatherhood, ...
CHICAGO – Among patients who have had an ischemic stroke, use of cholesterol-lowering statin medications is not associated with subsequent intracerebral hemorrhage (bleeding in the brain), according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.
According to background information in the article, after stroke or transient ischemic attack, patients are at increased risk for recurrent events. Results from the Stroke Prevention by Aggressive Lowering of Cholesterol Levels (SPARCL) trial and the Heart Protection Study (HPS) ...
CHICAGO – Intranasal insulin therapy appears to provide some benefit for cognitive function in patients with amnestic mild cognitive impairment and Alzheimer disease, according to a report published Online First today by Archives of Neurology, one of the JAMA/Archives journals.
According to background information in the article, insulin plays a role in a number of functions of the central nervous system. "The importance of insulin in normal brain function is underscored by evidence that insulin dysregulation contributes to the pathophysiology of Alzheimer disease (AD), ...
CHICAGO – Many U.S. adults believe that only extremely effective drugs without serious adverse effects are approved, but providing explanations to patients highlighting uncertainties about drug benefits may affect their choices, according to a report in the September issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The article is part of the journal's Less Is More series.
Approval from the U.S. Food and Drug Administration (FDA) does not necessarily ensure that a drug has a large or important benefit, or that all serious adverse effects of the ...
CHICAGO – Long-term use of nonaspirin anti-inflammatory drugs (NSAIDs) is associated with an increased risk of renal cell cancer (RCC), according to a report in the September issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
According to background information in the article, in the United States, kidney cancer is the seventh leading type of cancer among men and the ninth leading type of cancer among women. The most common type of kidney cancer, renal cell cancer, accounts for 85 percent of all cases. Analgesics (pain-relieving medications) are ...
CHICAGO – An association has been found between infection associated with cardiovascular implantable electronic devices (CIEDs) and increases in mortality and hospital care costs, according to a report published Online First by Archives of Internal Medicine, one of the JAMA/Archives journals. The article is part of the journal's Health Care Reform series.
Therapy with CIEDs, which include pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization therapy/defibrillator devices, can reduce illness and death rates in appropriately selected patients, ...
Skin Solutions Medical Spa has been serving the Denver Metro area for the past 15 years and was recently nominated for Denver 7's A-List as Denver's best Medical Spa. The spa stands out in the community by providing the highest level of customer service while producing state-of-the-art cosmetic procedures and aesthetic treatments that are safe and effective. The announcement of Express Rejuvenation Day shows the spa's commitment to provide even more quality to their clients and community.
Skin Solutions Medical Spa's new Express Rejuvenation Day was driven by the demand ...
A new set of harmonized guidelines for the management of risk factors for cardiovascular disease will make it much easier for physicians to care for their patients, according to the authors of the C-CHANGE guidelines published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj101508.pdf.
The Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) Initiative harmonized and integrated more than 400 separate recommendations from 8 sets of guidelines into one comprehensive but simplified resource. ...
Young children who watch fast-paced, fantastical television shows may become handicapped in their readiness for learning, according to a new University of Virginia study published in the October issue of the journal Pediatrics.
U.Va. psychologists tested 4-year-old children immediately after they had watched nine minutes of the popular show "SpongeBob SquarePants" and found that their executive function – the ability to pay attention, solve problems and moderate behavior – had been severely compromised when compared to 4-year-olds who had either watched nine minutes of ...
Monmouth Junction, NJ (September 12, 2011): A new study finds that infections following cardiac device implantations or replacement result in extremely high costs, both financially and in terms of patient mortality, even months after affected patients return home. Infections associated with pacemakers and defibrillators led to 4.8 to 7.7-fold increases in admission mortality, 1.6 to 2.1-fold increases long term mortality, 2.5 to 4.0-fold increases in hospital length of stay, and 1.4 to 1.8-fold increases in cost compared to pacemaker and defibrillator implantations without ...
